TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12512888

Group type: EXPERIMENTAL
Intervention: Ceramic filling material (CF)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Resin composite (RC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Enamel (E)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Customary oral hygiene
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Neglected oral hygiene
Number of subjects: 20
Study: 9161646

Group type: EXPERIMENTAL
Intervention: Carmapine (generic brand of carbamazepine)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Carzepine (generic brand of carbamazepine)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Tegretol (proprietary brand of carbamazepine)
Number of subjects: 18
Study: 7906572

Group type: EXPERIMENTAL
Intervention: n-3 PUFA-enriched eggs
Number of subjects: 23

Group type: COMPARATOR
Intervention: Regular eggs
Number of subjects: 23
Study: 3300903

Group type: EXPERIMENTAL
Intervention: Pinacidil
Number of subjects: 33

Group type: COMPARATOR
Intervention: Hydralazine
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 11823765

Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy
Number of subjects: 27849
Study: 30346669

Group type: EXPERIMENTAL
Intervention: GHP - 35% hydrogen peroxide gel
Number of subjects: 40

Group type: COMPARATOR
Intervention: GCP - 37% carbamide peroxide gel
Number of subjects: 40
Study: 26700703

Group type: EXPERIMENTAL
Intervention: Complete response (T0) after induction chemo-RT
Number of subjects: 119

Group type: COMPARATOR
Intervention: Near-complete response (Ta or Tis) after induction chemo-RT
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Complete response (T0) and near-complete response (Ta or Tis) after induction chemo-RT
Number of subjects: 119
Study: 24284437

Group type: EXPERIMENTAL
Intervention: Isoleucine (5‐216 mg · kg(‐1) · d(‐1))
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Leucine (5‐370 mg · kg(‐1) · d(‐1))
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Valine (5‐236 mg · kg(‐1) · d(‐1))
Number of subjects: 83
Study: 22929451

Group type: EXPERIMENTAL
Intervention: 1 drop of cyclopentolate 0.2% and phenylephrine 1% ophthalmic solution
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 2 drops of cyclopentolate 0.2% and phenylephrine 1% ophthalmic solution
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 3 drops of cyclopentolate 0.2% and phenylephrine 1% ophthalmic solution (treatment reference group)
Number of subjects: 15

Group type: COMPARATOR
Intervention: 0 drops of cyclopentolate 0.2% and phenylephrine 1% ophthalmic solution (control group)
Number of subjects: 15
Study: 21035594

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 18579668

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate 3000 mg/d
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate 3750 mg/d
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate 4500 mg/d
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Reformulated lanthanum carbonate
Number of subjects: 513
Study: 15771694

Group type: EXPERIMENTAL
Intervention: Family therapy programme for 6 months
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25
Study: 12466159

Group type: EXPERIMENTAL
Intervention: I(125) brachytherapy
Number of subjects: 650

Group type: COMPARATOR
Intervention: Control group (enucleation)
Number of subjects: 650
Study: 10622067

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 122
Study: 8963030

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg bid (R2)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg qhs (R1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg bid (N2)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg qhs (N1)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 6
Study: 1949222

Group type: EXPERIMENTAL
Intervention: 6M regimen (28 weeks)
Number of subjects: 2218

Group type: EXPERIMENTAL
Intervention: 8M regimen (36 weeks)
Number of subjects: 2218

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 2218
Study: 7450412

Group type: COMPARATOR
Intervention: Intravenous 16,16-dimethyl PGE2 at doses of 0.01 to 0.1 microgram/kg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Oral 16,16-dimethyl PGE2 at doses of 0.01 to 1.0 microgram/kg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Oral 16,16-dimethyl PGE2 at 1 microgram/kg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Intravenous 16,16-dimethyl PGE2 at 0.1 microgram/kg
Number of subjects: 11
Study: 31785009

Group type: EXPERIMENTAL
Intervention: 75% of maximal voluntary contraction (MVC)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 25% of maximal voluntary contraction (MVC)
Number of subjects: 15

Group type: COMPARATOR
Intervention: 0% (control session)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Untrained BB
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: SICI, SP, and ICF in either BB
Number of subjects: 15
Study: 30907817

Group type: EXPERIMENTAL
Intervention: Low-dose heparin (10,000 IU/day)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: High-dose heparin (starting at 15,000 IU/day, adjusted to achieve an activated partial thromboplastin time of 1.5 to 2.5 times the baseline)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Heparin groups (low and high dose combined)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no heparin dose)
Number of subjects: 88
Study: 29275371

Group type: EXPERIMENTAL
Intervention: Different dual antiplatelet therapy durations and stent types
Number of subjects: 2003
Study: 25659773

Group type: EXPERIMENTAL
Intervention: ELAPE
Number of subjects: 69

Group type: COMPARATOR
Intervention: Conventional APE
Number of subjects: 69
Study: 25402757

Group type: EXPERIMENTAL
Intervention: CCTA screening
Number of subjects: 900

Group type: COMPARATOR
Intervention: Standard national guidelines-based optimal diabetes care
Number of subjects: 900
Study: 22866292

Group type: EXPERIMENTAL
Intervention: 8 mg quick-release lornoxicam (LNX)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 19124815

Group type: EXPERIMENTAL
Intervention: Statin use at randomization (n = 397) for a median duration of at least 900 days over a median follow-up of 3.5 years.
Number of subjects: 1037
Study: 17474817

Group type: EXPERIMENTAL
Intervention: SSRI add-on therapy (sertraline, citalopram, paroxetine, fluoxetine, fluvoxamine)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: SSRI add-on therapy (for chronic patients)
Number of subjects: 393
Study: 16138575

Group type: EXPERIMENTAL
Intervention: Spraying the long‐acting antibacterial material JUS on the surface of catheter and urethral orifice
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional treatment of urethral orifice twice a day
Number of subjects: 60
Study: 11192336

Group type: COMPARATOR
Intervention: Placebo with clinical management
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Antidepressant
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Problem‐Solving Treatment
Number of subjects: 307
Study: 9473217

Group type: EXPERIMENTAL
Intervention: Oral hydroxyurea (80 mg/kg every 3 days)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Intravenous hydroxyurea (2000 mg as a 30-minute infusion)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Oral and intravenous hydroxyurea
Number of subjects: 29
Study: 7827633

Group type: EXPERIMENTAL
Intervention: Inertial training on the Impulse system, three times per week for 5 weeks, focusing on the nondominant arm.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 40
Study: 3151068

Group type: COMPARATOR
Intervention: GnRH withdrawal (Group A)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hourly GnRH pulses (Group B)
Number of subjects: 8
Study: 30395821

Group type: EXPERIMENTAL
Intervention: Intravenous patient‐controlled analgesia (PCA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Scheduled and as‐needed oral analgesia (non-PCA)
Number of subjects: 40
Study: 28392393

Group type: EXPERIMENTAL
Intervention: Nerve sparing prostatectomy augmented with seminal vesicle sparing
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard nerve sparing prostatectomy
Number of subjects: 140
Study: 26043913

Group type: COMPARATOR
Intervention: Pelvic floor muscle training (PFMT), electrical stimulation (ES) and biofeedback
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT), electrical stimulation (ES), biofeedback plus 1 mg intravaginal estriol (IE)
Number of subjects: 62
Study: 23520222

Group type: EXPERIMENTAL
Intervention: Risk assessment with the Short Term Assessment of Risk and Treatability (START) and shared care planning protocol
Number of subjects: 632

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 632
Study: 20795821

Group type: EXPERIMENTAL
Intervention: Clinical risk tools for preeclampsia
Number of subjects: 1687

Group type: EXPERIMENTAL
Intervention: Prediction model incorporating clinical risk factors
Number of subjects: 1687
Study: 19349323

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/d)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Metformin (2000 mg/d)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Both therapies
Number of subjects: 78

Group type: COMPARATOR
Intervention: Neither treatment
Number of subjects: 78
Study: 16625988

Group type: EXPERIMENTAL
Intervention: Almotriptan 25 mg under fasting condition (reference)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Almotriptan 25 mg under fed condition
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Almotriptan 25 mg under fasting and fed conditions
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Almotriptan 25 mg
Number of subjects: 16
Study: 14604605

Group type: EXPERIMENTAL
Intervention: 1.5 microg/kg clonidine i.v.
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (no psychiatric illness)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: PTSD with co-morbid depression
Number of subjects: 82
Study: 10870871

Group type: EXPERIMENTAL
Intervention: Milnacipran 50mg p.o. b.i.d.
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study: 8623859

Group type: EXPERIMENTAL
Intervention: Fetal electrocardiogram plus electronic fetal monitoring
Number of subjects: 214

Group type: COMPARATOR
Intervention: Electronic fetal monitoring alone
Number of subjects: 214
Study: 1582275

Group type: EXPERIMENTAL
Intervention: MESAM 4
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: HVI (Heart Rate Variability Index)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: ISI (Snoring Index)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Combination of ODI, HVI, ISI
Number of subjects: 56

Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 56
Study: 2414580

Group type: EXPERIMENTAL
Intervention: Guanfacine 3 mg infused over 1 h
Number of subjects: 6

Group type: COMPARATOR
Intervention: Idazoxan 0.2 mg/kg i.v. (control)
Number of subjects: 6
Study: 31280701

Group type: EXPERIMENTAL
Intervention: SEGUE-based communication education (experimental group)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98
Study: 28235524

Group type: EXPERIMENTAL
Intervention: LMA Fastrach intubating laryngeal mask airway (ILMA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Flexible bronchoscopy (FB)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 26401869

Group type: EXPERIMENTAL
Intervention: Minimally access hydrocelectomy (Group B)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Conventional hydrocelectomy (Jaboulay's procedure) (Group A)
Number of subjects: 124
Study: 22473855

Group type: EXPERIMENTAL
Intervention: CBCT + TCT
Number of subjects: 60

Group type: COMPARATOR
Intervention: TCT
Number of subjects: 60
Study: 22515496

Group type: EXPERIMENTAL
Intervention: Pain Exposure Physical Therapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 62
Study: 19300399

Group type: EXPERIMENTAL
Intervention: Voxel-Based Morphometry (VBM)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 21
Study: 17561600

Group type: EXPERIMENTAL
Intervention: Device closure of patent foramen ovale
Number of subjects: 1
Study: 15450785

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day) for 6 weeks
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day) for 6 weeks
Number of subjects: 33
Study: 12456439

Group type: EXPERIMENTAL
Intervention: Superia
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sofnolime
Number of subjects: 14
Study: 10631415

Group type: EXPERIMENTAL
Intervention: Patient controlled epidural analgesia with pethidine (15 mg of a 0.25% solution and a 10 minute lockout period)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Single bolus of epidural morphine 4 mg
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Patient controlled epidural analgesia with pethidine
Number of subjects: 78
Study: 8636370

Group type: EXPERIMENTAL
Intervention: Recombinant human GH administered sc daily at bedtime, target dose of 12 micrograms/kg x day
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Recombinant human GH
Number of subjects: 68
Study: 1763227

Group type: EXPERIMENTAL
Intervention: CDP-choline 2000 mg/die e.v. from two weeks before surgery to ten days after surgery, then 1000 mg/die i.m., 15 days per month for 6 months (Group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CDP-choline 100 mg/die from two weeks before surgery to six months after surgery (Group B)
Number of subjects: 40
Study: 6814227

Group type: EXPERIMENTAL
Intervention: Propranolol (60 to 320 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Verapamil (240 to 480 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3878652

Group type: EXPERIMENTAL
Intervention: Isoflurane administered at an inspired concentration of 0.5‐1.5% for 30 minutes after CPB.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fentanyl infusion continued during CPB (control group).
Number of subjects: 20
Study: 29091471

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ) supplementation (70-ml concentrated, 7.7 mmol)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (PLA; 0.1 mmol)
Number of subjects: 9
Study: 27621189

Group type: EXPERIMENTAL
Intervention: Cycling at 60% of their maximal oxygen uptake at 22°C for 40 min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Rest at 22°C for 40 min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cycling at 60% of their maximal oxygen uptake at 31°C for 40 min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Rest at 31°C for 40 min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Heat exposure (31°C)
Number of subjects: 10
Study: 24515273

Group type: EXPERIMENTAL
Intervention: AP301 (inhaled, single doses up to 120 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (inhaled)
Number of subjects: 48
Study: 22938661

Group type: EXPERIMENTAL
Intervention: SCys C-CCr
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: SCr-CCr
Number of subjects: 51

Group type: COMPARATOR
Intervention: APACHE II score
Number of subjects: 51

Group type: COMPARATOR
Intervention: Urine volume
Number of subjects: 51
Study: 20146803

Group type: EXPERIMENTAL
Intervention: Customised educational intervention combining practice-based workshops and electronic support material
Number of subjects: 200

Group type: COMPARATOR
Intervention: Normal care
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Customised educational intervention
Number of subjects: 200
Study: 19028434

Group type: EXPERIMENTAL
Intervention: Specific manipulation as adjunct to extension exercises
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no manipulation)
Number of subjects: 72
Study: 16104911

Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg once daily
Number of subjects: 0
Study: 14745215

Group type: EXPERIMENTAL
Intervention: Modified unilateral intradural ventral rhizotomy of C1 and C2, extradural denervation of C3‐C6 posterior rami, and contralateral peripheral sectioning of the branches of the accessory nerve to the sternocleidomastoid muscle (Taira's method: group A)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Traditional Bertrand's procedure (Bertrand's method: group B)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Modified unilateral intradural ventral rhizotomy of C1 and C2 (Taira's method: group A)
Number of subjects: 82
Study: 11423890

Group type: EXPERIMENTAL
Intervention: Peritoneal closure (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-repair of peritoneum (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 60
Study: 9025126

Group type: EXPERIMENTAL
Intervention: EMT‐1: 107 laypersons with basic life support (BLS) training
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: EMT‐2: 16 emergency medical technicians (EMTs) in training
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: PM‐1: 74 paramedics in training
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: PM‐2: 9 certified paramedics
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 16
Study: 1792912

Group type: EXPERIMENTAL
Intervention: S2 regimen with intermediate-dose methotrexate (ID-MTX)
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: S2 and H2 groups with ID-MTX
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Triple intrathecal injections (TIT)
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: 24Gy cranial irradiation (CRX)
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: HEX group regimen
Number of subjects: 498
Study: 6549837

Group type: EXPERIMENTAL
Intervention: Holding at delivery
Number of subjects: 37

Group type: COMPARATOR
Intervention: Not holding at delivery
Number of subjects: 37
Study: 31313410

Group type: EXPERIMENTAL
Intervention: Exenatide infusion (Day-A)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: l-NMMA infusion (Day-B)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (isotonic saline) (Day-A)
Number of subjects: 10
Study: 30358831

Group type: EXPERIMENTAL
Intervention: DP1-10 cocoa extract containing 130 mg (‐)‐epicatechin and 560 mg procyanidins
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: DP2-10 cocoa extract containing 20 mg (‐)‐epicatechin and 540 mg procyanidins
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control capsule (flavanol-free)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: DP1-10 and DP2-10
Number of subjects: 45
Study: 27448540

Group type: EXPERIMENTAL
Intervention: eHealth encouragement physical activity for 52 weeks
Number of subjects: 158

Group type: COMPARATOR
Intervention: Health education and individual counseling
Number of subjects: 158
Study: 25560690

Group type: EXPERIMENTAL
Intervention: Self-ligating brackets (Damon system)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional brackets (Roth technique)
Number of subjects: 22
Study: 22892745

Group type: EXPERIMENTAL
Intervention: Total-etch (TE) sealer
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Self-etch (SE) sealer
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Epoxy resin-based (EP) sealer
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not preincubated)
Number of subjects: 45
Study: 19843354

Group type: EXPERIMENTAL
Intervention: Face-to-face counselling
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Telephone counselling
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bibliotherapy
Number of subjects: 90
Study: 17378788

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia plus epidural MgSO(4) (2%, 100 mg/h)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia plus intrathecal MgSO(4) (94.5 mg, 6.3%)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intrathecal and epidural MgSO(4) combined
Number of subjects: 120

Group type: COMPARATOR
Intervention: Spinal anesthesia alone (control)
Number of subjects: 120
Study: 16277798

Group type: EXPERIMENTAL
Intervention: Community-based dietary intervention (dietary diversification, changes in food selection patterns, modifications to food processing)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Community-based dietary intervention
Number of subjects: 281

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 281
Study: 12230335

Group type: EXPERIMENTAL
Intervention: Multicycle-run training
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal training
Number of subjects: 12
Study: 9505567

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) used off-label in conjunction with antibiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 0
Study: 8079178

Group type: EXPERIMENTAL
Intervention: Hand-sewn anastomosis
Number of subjects: 113

Group type: COMPARATOR
Intervention: Stapled anastomosis
Number of subjects: 113
Study: 2480741

Group type: EXPERIMENTAL
Intervention: Ornithine oxoglutarate (Cetornan)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 785084

Group type: EXPERIMENTAL
Intervention: beta‐acetyldigoxin and Bencyclan (Verum)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (beta‐Acetyldigoxin)
Number of subjects: 46
Study: 31771409

Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging (DTI)
Number of subjects: 75

Group type: COMPARATOR
Intervention: T2-weighted imaging
Number of subjects: 75
Study: 30790069

Group type: EXPERIMENTAL
Intervention: Pegilodecakin monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pegilodecakin in combination with anti-PD-1 inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pegilodecakin with FOLFOX
Number of subjects: 0
Study: 27878543

Group type: EXPERIMENTAL
Intervention: Oronasal model
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Nasal model
Number of subjects: 332
Study: 25731073

Group type: EXPERIMENTAL
Intervention: Educational intervention (one-page information sheet about hydrocodone-acetaminophen, given and read aloud)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 274

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 274